Dr. Jonathan W Friedberg, MD

Jonathan W. Friedberg, M.D., is Director of the James P. Wilmot Cancer Center, Chief of Hematology/Oncology and Director of Hematological Malignancies Clinical Research. He is a driving force behind the operations of our clinical programs and a key member of the center's lymphoma Specialized Program of Research Excellence, funded by the National Cancer Institute. Friedberg is a member of the lymphoma committee in the Southwest Oncology Group, and serves as principal investigator on many local and national lymphoma treatment protocols for both Hodgkin lymphoma and non-Hodgkin's lymphoma. Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation. He holds subspecialty …certification in Medical Oncology and Hematology. His research interests focus on development of novel therapies for patients with lymphoma. Most recently, he was awarded the Scholar in Clinical Research award from the Leukemia & Lymphoma Society, based upon his work with an oral inhibitor of a protein called Syk, which demonstrated efficacy in the treatment of several different forms of lymphoma, and was selected as a plenary presentation at the annual meeting of the American Society of Hematology.